Pembrolizumab in Treating Participants With Leukoplakia

Conditions:   Erythroleukoplakia;   Leukoplakia;   Verrucous Oral Leukoplakia
Intervention:   Biological: Pembrolizumab
Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI);   Merck Sharp & Dohme Corp.
Not yet recruiting

https://ift.tt/2NPtoXf